Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Patients with detectable CD274 (Programmed death-ligand 1 (PD-L1))+ Circulating Tumor Cells (CTCs) (14/25, 64%) had significantly longer progression-free survival (PFS) compared with patients with CD274 (Programmed death-ligand 1 (PD-L1))− Circulating Tumor Cells (CTCs) (26.6 months vs. 5.5 months; p = .018). The 12-month PFS rates were 76% versus 22% in the CD274 (Programmed death-ligand 1 (PD-L1))+ versus CD274 (Programmed death-ligand 1 (PD-L1))− Circulating Tumor Cells (CTCs) groups (p = .012), respectively. A multivariate linear regression analysis confirmed that CD274 (Programmed death-ligand 1 (PD-L1))+ Circulating Tumor Cells (CTCs) is an independent predictive [biomarker](brain:…